The fate of mRNA is regulated by epitranscriptomic nucleotide modifications, the most abundant of which is N A in mRNA is mediated by specific methyltransferases, a recent hypothesis is that specific demethylases or 'erasers' allow m 6 A to be dynamically reversed by signaling pathways. In this Review, we discuss the data in support and against this model. New insights into the function of fat mass and obesity-associated protein (FTO), the original enzyme thought to be an m A may be susceptible to demethylation in pathophysiological states such as cancer.
A to be dynamically reversed by signaling pathways. In this Review, we discuss the data in support and against this model. New insights into the function of fat mass and obesity-associated protein (FTO), the original enzyme thought to be an m 6 A eraser, reveal that its physiologic target is not m 6 A, but instead is N
6
,2 0 -Odimethyladenosine (m 6 A m ). Another m 6 A demethylase, ALKBH5, appears to have functions limited to sperm development in normal mice. Overall, the majority of the data suggest that m 6 A is generally not reversible, although m 6 A may be susceptible to demethylation in pathophysiological states such as cancer.
Keywords: ALKBH5; epitranscriptome; fat mass and obesity; N 6 -methyladenosine; N Epitranscriptomic regulation of mRNA A major goal in molecular biology is to understand the rules that explain the amount of each protein that is produced in the cell for every gene in the genome. The amount of protein is related to the amount gene transcription that generates the mRNA that encodes the protein. However, the levels of protein synthesis often do not correlate with mRNA transcription rates [1] . This finding has suggested that various mechanisms affect the mRNAs that ultimately determine the amount of protein synthesized in the cell. The attempt to understand post-transcriptional gene regulatory mechanisms led to the reemergence of the field of epitranscriptomics. We coined the term 'epitranscriptomic' to describe the idea that mRNA and lncRNA contain additional information beyond their encoded nucleotide sequence [2] . This information is stored in nucleotide modifications-usually methylation -that are often 'invisible' to ribosomes and reverse transcriptase enzymes. As a result, they do not change the amino acid sequence of the encoded protein but instead affect translation initiation, stability, localization, or function of RNAs. Importantly, when mRNAs are reversed transcribed to cDNA, any record of these methyl marks is lost, since the methylated nucleotide is reverse transcribed in the same way as the nonmethylated nucleotide. The term 'epitranscriptomic' is now often used to refer to any nucleotide modification that alters the function or properties of an RNA.
The idea that nucleotide modifications in mRNA can influence gene expression is not new. Although the research community paid little attention to this form of regulation until recently, N was known to be a highly pervasive modification in mRNA based on studies of the nucleotide composition of poly(A) RNA in 1974 [3, 4] . However, the interest in m 6 A largely faded by the late 1970s due to a lack of methods for detecting m 6 A sites in specific mRNAs. At the time, m 6 A detection was limited to quantifying m 6 A in nuclease digests of RNA preparations. In addition to not knowing which mRNAs contained m 6 A, there were also concerns that m 6 A could arise from RNA species that contaminate poly(A) mRNA fractions.
The realization that m 6 A is a regulatory mark came with the finding that m 6 A has a central role in developmental processes. The m 6 A methyltransferase was purified and cloned by Rottman et al. in 1997 (originally named MT-A70, and now called methyltransferase-Like 3, or METTL3) [5, 6] . Once METTL3 was cloned, the role of m 6 A could then be explored. The first study to explore the function of m 6 A was performed in yeast, where m 6 A levels in mRNA were found to be dynamic during yeast sporulation [7] . The importance of m 6 A was established based on the finding that loss of the yeast METTL3 homolog markedly impairs yeast sporulation [7] . Similarly, loss of the plant METTL3 ortholog caused a block in seed development in plants [8] . The finding that deletion of the METTL3 orthologs in plants and yeast caused profound and selective effects on development was the seminal studies that demonstrated that m 6 A is required for specific steps during development. These studies spurred interest in developing m 6 A-mapping technologies to identify the mRNA methylation events that regulate developmental processes.
The ability to study m 6 A and link m 6 A with cellular processes became mainstream as a result of MeRIP-Seq, a next-generation sequencing method to map m 6 A throughout the transcriptome. This method, developed in 2012 by our group and independently by the Rechavi group [2, 9] , revealed that m 6 A was unequivocally an mRNA modification, and surprisingly showed that m 6 A was highly selective: only certain mRNAs contained m 6 A, and m
A is often located near stop codons and in 3 0 UTRs. m 6 A levels in mRNA were found to be dynamic, with levels varying in development and in response to cellular stresses [2, 9] . These studies strongly suggested that m 6 A is likely to have functional roles that affect mRNA fate and function in cells.
Since that time, MeRIP-Seq has been used in nearly all studies on m 6 A and has led to the identification of numerous methylated mRNAs that appear to have critical roles in cellular processes such as cancer and cellular differentiation. The m 6 A-mapping concept was quickly applied to other modified nucleotides, resulting in transcriptome-wide maps of N 6 ,2 0 -O-dimethyladenosine (m 6 A m ) [10] , 5-methylcytidine (m 5 C) [11] [12] [13] , pseudouridine [14] [15] [16] , 5-hydroxymethylcytidine (hm 5 C) [17] , 2 0 -O-methylated nucleotides (N m ) [18] , and N 1 -methyladenosine (m 1 A) [19, 20] . However, the validity of the mapping results for some other nucleotides, such as m 5 C, m 1 A [21] , and N m [22] has been challenged. Further analysis showed that the mapping approaches were susceptible to nonspecific signals or sequencing artifacts that were incorrectly attributed to nucleotide modification [22] [23] [24] . Based on these discrepancies, the modifications that are unambiguously thought to be present in mammalian mRNA currently are m 6 A (~8000 or more sites), m 6 A m (~2000 or more sites), and pseudouridine (~400 or more sites) [22] .
Reversible RNA modification hypothesis and FTO
Although the m 6 A profile was thought to be mediated by the m 6 A writer METTL3, a new hypothesis was that m 6 A levels are also determined by m 6 A 'erasers', which are enzymes that demethylate m 6 A, reforming adenosine [25] . Reversibility of m 6 A could make this modification analogous to other reversible modifications, such as 5-methyl cytosine in DNA and various protein modifications such as phosphorylation in proteins. This concept is particularly exciting since it raises the possibility that RNA modifications would be formed and removed in a dynamic, signal-dependent manner.
The idea of reversible RNA methylation derived from studies of fat mass and obesity-associated protein (FTO). Mutations in the FTO gene are linked to obesity, although, as described below, it is now thought that these mutations do not affect the FTO protein, but instead have a regulatory effect on genes adjacent to FTO. Nevertheless, the belief that FTO controlled human obesity led to intense interest in understanding its function. Although FTO was initially a protein of unknown function, the advance in this area came from a reanalysis of the amino acid sequence of FTO, and the realization that FTO contained sequence motifs resembling those found in the ALKB family of dioxygenase enzymes [26] . These enzymes were previously shown to act on DNA and RNA nucleotides that are damaged by exogenous alkylating agents [27, 28] . A screen for substrates showed that FTO is indeed a demethylase and exhibits demethylase activity toward 3-methylthymidine in DNA [26] .
The next major step was the finding that FTO can act on RNA. He and colleagues further explored FTO substrate specificity and showed that FTO exhibits slightly higher preference for 3-methyluridine (m 3 U) in RNA than 3-methylthymidine in DNA [29] . The authors of this study proposed that FTO might function to demethylate m 3 U modifications that occur naturally, rather than modifications that arise as a result of RNA damage.
In a subsequent study, this group showed that FTO could also demethylate m 6 A in mRNA using in vitro reactions [25] . Subtle decreases in m 6 A in poly(A) mRNA were seen in cells that overexpressed FTO, and slight increases in m 6 A were seen in FTO-depleted cells [25] . These data provided the initial support for the idea that RNA modifications m 3 U and m 6 A could be reversed by FTO. Since mRNA contains m 6 A and not m 3 U, and because FTO shows 50-fold greater demethylation activity on m 6 A than m 3 U, FTO's action on m 6 A was proposed to be the physiologically relevant activity of FTO [25] . The authors also proposed that FTO-mediated m 6 A demethylation might serve as a mRNA regulatory mechanism [25] .
The localization of FTO makes it seem unlikely that FTO is a dynamic regulator of m 6 A levels. FTO is primarily, and potentially exclusively in the nucleus [25, 26] , making it unclear how it would dynamically regulate m 6 A in mRNA, which is primarily cytosolic. mRNA is only present in the nucleus when it is transcribed. As a result, FTO can only demethylate m 6 A in mRNA during a very short window following its biogenesis. Therefore, FTO-mediated RNA demethylation cannot be dynamic with respect to cytosolic mRNAs.
Until recently, few studies followed up on the idea that FTO regulates m 6 A levels in cellular mRNA including from the groups that introduced the idea. Despite this, the idea of reversibility remains an important, yet unresolved hypothesis.
Conflicting evidence about relevance of FTO to obesity and leukemia FTO was a particularly intriguing enzyme since FTO gene mutations were linked to obesity. As a result, the finding that FTO is an RNA demethylase immediately suggested that alterations in RNA demethylation could be intimately involved in human metabolism and obesity [30] . FTO mutations are the most common genetic contributor to obesity with~1 in 7 people having at least one obesity-linked FTO mutation [30] .
However, the FTO enzyme and its demethylase activity is no longer thought to be relevant to human obesity. More recent studies show that obesity-linked FTO mutations do not affect the FTO protein; instead, they affect the expression of neighboring genes [31] [32] [33] . These mutations are primarily located in intron 1 of FTO, and chromosome interaction analysis showed that this region is an enhancer that controls the expression of neighboring genes Irx3 and RPGRIP1L [31] [32] [33] . Despite extensive studies, there is no definitive evidence that the human obesity-associated FTO mutations affect the FTO protein or its expression. Thus, human obesity is linked to mutations within the FTO gene, but these mutations affect an intron-localized enhancer that controls expression of neighboring genes, not FTO itself.
More recent work suggested that FTO is a novel oncogene that promotes acute myeloid leukemia (AML) [34] . This study argued that elevated levels of FTO are seen in AML, and depleting FTO impairs AML growth and proliferation. However, another study demonstrated the opposite result, that is, that FTO has no effect on AML growth [35] . The latter study examined an extensive CRISPR screen using 14 genetically diverse AML cell lines which was designed to identify essential growth regulators and oncogenes in AML [36] . In this screen, oncogenes are readily identified since their CRISPR-mediated depletion results in reduced growth of AML cell lines [36] . However, examination of the results of the CRISPR screen showed that FTO depletion had minimal growth effects on the majority of the 14 AML cell lines tested [35] . This contrasts with other oncogenes, which had clear growth inhibitory effects when deleted in this CRISPR screen [36] . FTO deletion only exhibited a prominent effect in an atypical AML line associated with eosinophilia. Additionally, recent pan-cancer studies, such as Project DRIVE, detected no general FTO-dependency of hematological cancers [37] . Thus, FTO does not behave like known oncogenes in these unbiased CRISPR screens.
In contrast to the putative eraser, m 6 A writers have an oncogene-like effect in AML. Elevated m 6 A writer complex components and elevated m 6 A caused AML growth and proliferation [35, 38] . Thus, it appears that elevated m 6 A, rather than reduced m 6 A, has an oncogenic effect. The finding that FTO is an oncogene is inconsistent with the comprehensive CRISPR screens in AML lines. The pro-leukemic FTO effect may be limited to specific cell lines or conditions used in that study, rather than a general feature of AML.
Although it is now clear that FTO has no role in human obesity, and an oncogenic role for FTO in AML seems to be contradicted by global screening approaches, it is clear that FTO influences physiology. We and others examined the FTO knockout mouse to understand physiologic functions of this enzyme [39, 40] . FTO knockout mice are largely normal except for alterations in dopaminergic neurotransmission, lean body mass, and alterations in metabolic rate [39, 40] . In addition, FTO knockout mice exhibit increased postnatal death and are born with reduced Mendelian ratios, that is, a reduced number of homozygote FTO-deficient offspring [40] . Thus, FTO is required for various physiologic functions in mice.
The function of FTO in humans seems different from its role in mice. The function of FTO in humans has been extrapolated based on examination of a family that carries a FTO allele containing an enzymeinactivating point mutation [41] . Family members homozygous for this FTO mutation exhibit early childhood death along with microcephaly, severe psychomotor delay, functional brain deficits, postnatal growth retardation, facial dysmorphism, and other severe developmental defects [41] . These human phenotypes are different and more severe than the phenotype seen in mice, where neurodevelopmental abnormalities and malformations are not seen [40] .
Although FTO is not linked to obesity, it is clear that FTO, and presumably its RNA demethylase activity, has important roles in physiological processes in cells and tissues.
Inconsistencies with m 6 A as the substrate of FTO Although FTO clearly exhibits demethylation activity toward m 6 A in vitro, diverse lines of evidence suggests that FTO does not physiologically act on m 6 A. Chronologically, the argument against the idea of m 6 A reversibility is based on early studies in 1978 in which m 6 A levels were tracked in mRNA from biogenesis to degradation [42] . Using radiolabeled metabolic tracer studies, Darnell and colleagues demonstrated that m 6 A levels are constant in mRNA until the mRNA degrades [42] . These authors concluded that once m 6 A is formed, it is not subsequently removed. Darnell and colleagues replicated this finding more recently using more sensitive m 6 A-detection methods and m 6 A mapping techniques [43] . Their reanalysis nearly 35 years after their initial study came to the same conclusion [44] . It should be noted that their inability to detect m 6 A loss from mRNA does not exclude the possibility that m 6 A demethylation is elicited by some type of signal that was not used in their assays.
The second problem with the idea that FTO demethylates m 6 A is its unusually low reaction rates toward m 6 A. Typically, enzymes are characterized by their catalytic efficiency. This is critical because many enzymes will act on virtually any target at a very slow rate, while acting on their physiological intended target at a much higher rate. Indeed, the finding that FTO exhibits 50 times higher activity toward m 6 A compared with m 3 U lead to the conclusion that m 6 A is the physiologically relevant substrate [25] . However, despite the higher activity of FTO toward m 6 A compared with m 3 U, FTO's catalytic efficiency toward m 6 A is still much lower than the catalytic activity of other dioxygenase enzymes toward their substrates [25] .
Notably, to detect m 6 A demethylation, the initial studies that tested FTO's activity toward m 6 A used m 6 A RNA that was only in five-fold molar excess over FTO. Traditionally, substrates are used at hundreds or thousands of times of excess over the enzyme since the enzyme can perform multiple turnovers. However, the low turnover rate required an unusually high amount of FTO to result in detectable demethylation. Based on these parameters, FTO's activity toward m 6 A has the hallmarks of a nonspecific reaction, rather than a specific reaction.
The slow reaction time is particularly important because demethylation of m 6 A would have to occur in the nucleus prior to mRNA export. Because mRNAs are typically exported in < 15 min [45] , a slow reaction rate would make FTO-mediated demethylation highly ineffective.
An additional problem is that FTO does not show sequence-specific demethylation of m 6 A. The original studies on FTO-mediated m 6 A demethylation [25] , as well as follow-up studies [46] , showed that FTO efficiently demethylates m 6 A irrespective of sequence context. For example, m 6 A is as efficiently demethylated when placed within a poly(U) or poly(C) sequence or its natural sequence context (purine -m 6 A -cytidine) [47] . Most modifying enzymes for proteins, RNA, and DNA show sequence context specificity to achieve high affinity and selectivity toward their target. The absence of selectivity toward m 6 A within its natural sequence context is highly suggestive of a nonspecific interaction.
The pattern of endogenous binding of FTO in the transcriptome is also not consistent with its action on m 6 A. A recent study used cross-linking and immunoprecipitation RNA-seq (CLIP-seq) to identify binding sites of FTO on cellular mRNAs [48] . CLIP is typically used to map the transcriptome-wide binding properties of RNA-binding proteins [49] . CLIP analysis of FTO-binding sites showed that the FTO-binding sites are selectively de-enriched for the m 6 A consensus site [48] . Although it is possible that FTO binds to a highly select subset of m 6 A sites, potentially determined by RNA structure or some other feature, the general global de-enrichment of FTO from m 6 A consensus sites seems to suggest that FTO does not bind m 6 A in a cellular context. The crystal structure of FTO has not provided insight into binding to m 6 A, while the structure of ALKBH5 shows a clear m 6 A-binding pocket [50] [51] [52] .
First, it should be noted that FTO has not yet been successfully crystallized with m 6 A. Instead, FTO has been crystallized with 3-methyl thymidine [53] , a substrate that was the initially identified FTO substrate. Therefore, it is not yet known how FTO might interact with m 6 A. However, structural studies of ALKBH5 show that its 'nucleotide-recognition lid', the region that determines substrate binding in this family of demethylases, exhibits specific contacts that account for its specific recognition of m 6 A [50] [51] [52] . These contacts could explain why ALKBH5 demethylates m 6 A in a sequence-specific manner, that is, in a purinem 6 A-C sequence context. Although FTO is in the same enzyme family, the nucleotide-recognition lid is highly divergent from the one in ALKBH5, suggesting that FTO has a different substrate than ALKBH5.
Lastly, transcriptome-wide analysis of m 6 A in brain mRNA from the FTO knockout mouse did not show a clear and robust increase in m 6 A sites in the transcriptome [39] . Presumably, after the deletion of an m 6 A eraser, m 6 A stoichiometries should be highly elevated. Instead, there was very minimal evidence for a global increase in m 6 A [39] . Because the MeRIP-seq method is relatively noisy, it is difficult to compare samples because even biological replicates show considerable variation in peak heights [22] . Nevertheless, even considering the degree of variation, and including replicates, there was only a subtle increase in the number of m 6 A sites that were detected in the FTO knockout compared with the wild type [39] . As described below, these sites turned out to not be m 6 A but another nucleotide that was inadvertently detected using the MeRIP-seq technique due to cross-reactivity with the m 6 A antibody used in this method. Thus, analysis of the FTO knockout showed the lack of a robust increase in m 6 A, suggesting that FTO does not physiologically target m 6 A. In addition to these findings, numerous studies of m 6 A in diverse physiological contexts failed to find that FTO knockdown shows an opposite effect of METTL3 knockdown [54] . FTO knockdown should show the opposite effect as METTL3 knockdown if FTO removes m 6 A. These numerous and diverse problems with the concept that FTO targets m 6 A suggest that the demethylase activity of FTO involves a different nucleotide.
Discovery of the physiologic target of FTO: m 6 A m
We recently sought to understand why only a few m 6 A residues were affected in the transcriptome of FTO knockout mice [39] . One possibility is that FTO only demethylates specific m 6 A residues, accounting for the lack of a global increase in m 6 A levels. This argument seemed unlikely since all m 6 A residues are in the same general consensus site [10] , so each m 6 A should be equally susceptible to FTO. Nevertheless, when we performed a detailed reanalysis of m 6 A peak intensities in wild-type and FTO knockout mice, we found that m 6 A peaks showed subtle elevation if they were in the 5 0 UTR [55] . Based on this, we suspected some feature of the 5 0 UTR accounts for the selectivity of FTO toward m 6 A in these sites. The next major advance was the realization that the 5 0 UTR is the site of a different RNA modification:
A m is similar to m 6 A in that they both contain a N 6 -methylated adenine ring. The original study that showed that FTO demethylates m 6 A did not test m 6 A m , the other 6-methyladenine-containing nucleotide. Importantly, m 6 A m is highly prevalent and is found in 30-40% of mRNAs adjacent to the N 7 -methylguanosine (m 7 G) cap at the first encoded nucleotide position [56] . m 6 A m may be found on more mRNAs than m 6 A, although m 6 A is present, on average, at more sites per mRNA [56] .
It should be noted that m 6 A m is readily detected by biochemical methods, such as TLC, but it is more difficult to detect by mass spectrometry. In mass spectrometry, nucleases are used to cleave at the 5 0 side of nucleotides in mRNA, resulting in mononucleotides. However, in this method, m A m . Thus, TLC is typically used to quantify m 6 A m . This approach has revealed that it is a highly prevalent nucleotide specifically and exclusively localized at the transcription-start nucleotide of certain mRNAs [56, 57] .
When we tested whether m 6 A m is a substrate of FTO, we found that FTO indeed targets m 6 A m , with remarkably high catalytic efficiency. In our assays, we found a ten-fold lower catalytic activity of FTO toward an m 6 A-containing substrate than had been previously reported [25] . For this reason, we compared RNAs that contained m 6 A and m 6 A m side-by-side using identical conditions to determine which nucleotide was the preferred substrate of FTO. In these experiments, we found that FTO exhibits nearly 100 times greater catalytic activity against m 6 A m is the most efficiently demethylated target of FTO identified to date. m 6 A was originally presumed to be the substrate of FTO based on its ability to be demethylated with 50-fold greater efficiency than m 3 U [25] . The 100-fold increased efficiency of FTO toward m 6 A m suggests that m 6 A m is the physiologically relevant substrate.
Notably, quantitative measurements of m 6 A m in poly (A) RNA showed significant increases in m 6 A m in FTO knockout cells compared with wild-type cells. In contrast, expression of a cytoplasmically localized FTO caused a reduction in m 6 A m . These experiments revealed that m 6 A m can be regulated by FTO in cells [55] . Importantly, there was no detectable increase in m 6 A in FTO knockdown HEK293 cells and FTO knockout embryos [55] . Expression of a cytoplasmically localized FTO also had no effect on m 6 A. These data suggest that FTO does not physiologically affect m 6 A. Additional studies showed that m 6 A m renders mRNAs less susceptible to decapping, thereby contributing to the markedly elevated mRNA stability associated with mRNAs containing m 6 A m [55] . Thus, m 6 A m is an epitranscriptomic mark that has functional consequences on mRNA stability.
Could FTO physiologically target m 6 A despites its inefficient demethylation of m 6 A?
Although FTO shows slow demethylation rates toward m 6 A, and FTO depletion results in no increase in m 6 A in FTO-deficient HEK293 cells and FTO knockout embryos [55] , it is nevertheless conceivable that FTO might act on specific m 6 A residues. Although there is no experimental evidence that supports any of these models, it is possible that the activity of FTO toward m 6 A could be induced by a post-translational modification or by an accessory protein that brings FTO to an m 6 A site and facilitates an otherwise unfavorable demethylation reaction.
Another possibility is that FTO could cause random, low-level demethylation across the transcriptome on nascent mRNAs. In this model, the activity of FTO would be nonspecific and no single m 6 A peak would be seen as upregulated when using MeRIP-seq in FTO-deficient cells. This model would not be consistent with a robust and selective regulatory function of FTO.
It should be noted that one study recently identified an increase in m 6 A in the MYC mRNA in leukemia cells after FTO depletion [34] . The identification of the FTO-regulated m 6 A site was based, in part, on the identification of increased m 6 A peak intensity in the MYC mRNA using MeRIP-Seq analysis of FTOdepleted leukemia cells [34] . A problem with detecting FTO-regulated m 6 A peaks using MeRIP-Seq is the high degree of variability in the peak measurements using this method [22] . In order to use MeRIP-Seq to detect changes in m 6 A between different conditions, it is important to measure the statistical variability in peak heights among a sufficient number of biological replicates. In this way, any difference in peak height can be assigned a P-value to determine whether the peak height is statistically significant with respect to the noisiness of peak height measurement. This statistical approach is generally not used, which makes it difficult to evaluate whether any peak differences that are detected by comparing MeRIP-seq datasets are meaningful.
Due to the noise of these assays along with other measures of m 6 A such as qRT-PCR analysis of m 6 A antibody-immunoprecipitated mRNA [22] , more rigorous methods need to be used. In particular, the major methods for measuring m 6 A levels at any site are techniques such as site-specific cleavage and radioactivelabeling followed by ligation-assisted extraction and thin-layer chromatography (SCARLET) [58] . This approach reveals the precise stoichiometry of m 6 A at any site and can be used to determine if any individual site has altered m 6 A levels. Importantly, this method has been used to examine m 6 A levels in mRNA [58] .
As of yet, no FTO-regulated m 6 A site has been validated using the SCARLET method. In addition, to the best of our knowledge, no m 6 A peak that was detected by MeRIP-Seq has been shown to change in an FTO-dependent manner statistically significant based on the variability of m 6 A peak measurements. It should be noted that measurements of m 6 A when depleting FTO can be convoluted by nonspecific effects on the m 6 A writer complex. For example, RNA-Seq expression data of FTO-depleted cells [34] showed a co-occurring 20% increase in the expression of the METTL14 transcript, which could explain the reported increase in m 6 A levels in these cells [22] . Thus, m 6 A measurements can be influenced by indirect gene expression effects especially after FTO knockdown. A m , preventing definitive identification of nucleotide identity
One reason for the confusion about the substrate specificity of FTO is that many studies have studied FTO using antibodies that bind m 6 A, without realizing that these antibodies also bind m 6 A m . In some experiments, the antibodies are used to immunoprecipitate m 6 A-containing RNAs for quantification of m A m that is changing in the RNA. This nonselectivity is one reason why ELISA experiments using m6A antibodies are also often not reliable.
Similarly, some studies have measured m 6 A levels after FTO depletion or overexpression in experiments in which mRNA was either spotted on a membrane or resolved on a gel and transferred to a membrane, similar to a northern blot. The blots were then immunoblotted with m 6 A antibodies, without realizing that the signals could reflect changes in m 6 A m . Indeed, prior to our own recognition of the prevalence of m 6 A m and its regulation by FTO, we used immunoblotting with m 6 A antibodies and observed a reduction in the m 6 A signal in immunoblots after high-level FTO overexpression [2] . Although this could reflect the nonselective activity of FTO toward m 6 A when FTO is highly overexpressed, this could have also reflected demethylation of m 6 A m . Overall, reagents such as m 6 A antibodies cannot be used to study m 6 A due to their nonselectivity, while techniques such as miCLIP, which distinguish these nucleotides [10] , currently remain the only method to distinguish these structurally similar modifications.
An alternative m 6 A demethylase: ALKBH5
Although FTO turned out to target m 6 A m , an additional m 6 A demethylase, ALKBH5, was also identified [59] . ALKBH5 was initially discovered in a biochemical screen for demethylase proteins that exhibit m 6 A demethylase activity [59] . ALKBH5 knockdown resulted in subtle increases in m 6 A in poly(A) RNA, while ALKBH5 overexpression caused subtle decreases in m 6 A in poly(A) mRNA. These data supported the idea that ALKBH5 might regulate m 6 A in mRNA [59] . Notably, unlike FTO, ALKBH5 has no activity toward m 6 A m and appears selective for m 6 A [55] . Although ALKBH5 is an m 6 A demethylase, it does not appear to have a meaningful role in most tissues. This conclusion is based on analysis of ALKBH5 knockout mice, which are largely normal except for defects in spermatogenesis [59] . Notably, ALKBH5 is highly expressed in testis, further supporting the idea that ALKBH5 function is primarily linked to a m 6 A demethylation event that is critical for sperm physiology and not other tissues [59] . Based on the otherwise normal phenotype of ALKBH5 knockout mice, none of the diverse signaling pathways required for mouse development and normal adult mouse function require ALKBH5-mediated m 6 A demethylation. Although the animals appear normal, it is possible that subtle phenotypes will be detected following further analysis of the ALKBH5 knockout mouse. Nevertheless, it is clear that ALKBH5-mediated demethylation of m 6 A is not required in most mouse tissues, while ALKBH5 activity is important in sperm cells. These cells may require m 6 A demethylation for their function or survival. As with FTO, the localization of ALKBH5 is in the nucleus [59] . As such, it makes it unlikely that ALKBH5 demethylates m 6 A in mature mRNA in the cytoplasm. Instead, ALKBH5 likely demethylates m 6 A during mRNA biogenesis in the nucleus. ALKBH5 could also demethylate m 6 A in nuclear-enriched m 6 Acontaining ncRNAs, such as snoRNAs, snRNAs, MALAT1, or NEAT1 [10] .
In contrast to normal cells, ALKBH5 appears upregulated in certain cancers. This has been detected in breast cancer cells [60] and glioblastoma stem cells [61, 62] . Thus, ALKBH5 may be upregulated in disease contexts, and in these contexts, ALKBH5 may modify the epitranscriptome.
Few studies have shown specific mRNA m 6 A sites that are increased in ALKBH5-depleted cells. In one case, NANOG mRNA was shown to exhibit decreased m 6 A levels in breast cancer cells that show elevated ALKBH5 levels [60] . Subsequent studies showed that these cells also have decreased methyltransferase activity, making it unclear if the reduced m 6 A levels in NANOG mRNA are due to increased ALKBH5 or decreased methyltransferase activity [63] .
Another study identified the FOXM1 transcript as a target of ALKBH5 [61] . In this study, the authors identified a noncoding antisense FOXM1 transcript that forms a duplex with the sense FOXM1 mRNA, making the sense FOXM1 transcript a substrate for ALKBH5 [61] . If the formation of an RNA-RNA duplex is generally required for ALKBH5 function, then ALKBH5 may be highly selective for mRNAs in specific structural contexts such as double stranded RNA.
Overall, these data suggest that ALKBH5 and m A; however, it is now clear that it acts on a different nucleotide, m 6 A m . The concept that FTO reverses RNA modifications may indeed be valid, except for that the correct FTO-regulated modification is m 6 A m . Nevertheless, it remains to be determined which m 6 A m -containing RNAs need to be demethylated by FTO in order to maintain normal dopaminergic neuron function, metabolism, or to ensure normal development in humans. Since FTO is localized to the nucleus, FTO may affect m 6 Am in nascent mRNAs, or other nuclear RNAs and noncoding RNAs. Nevertheless, the identification of m 6 A m as the physiological substrate of FTO is an important step forward in determining how RNA demethylation influences human physiology.
Another major principle that is apparent from studies of both FTO and ALKBH5 is that RNA demethylation is a nuclear event. Thus, if either of these enzymes act on mRNA, they would only be able to act on mRNA during the short period of time after transcription and before nuclear export. This makes it unlikely, if not impossible, that either of these enzymes dynamically regulate cytoplasmic mRNA in response to signaling pathways. Thus, mRNA demethylation is unlikely to occur in the same dynamic manner that is normally seen with reversible modifications in protein and DNA.
Another important concept is that the methylation and the reversibility of m 6 A is unlikely to be a general feature of epitranscriptomic regulation. Instead, m 6 A demethylation occurs in very unique circumstances. During normal development, m 6 A demethylation is likely to be prominent primarily in sperm. This is based on the highly selective sperm development phenotypes seen in the ALKBH5 knockout mouse. These mice clearly show normal development throughout the rest of the body demonstrating that animal development is fundamentally independent of m 6 A demethylation. When is m 6 A demethylation important? It is noteworthy that ALKBH5 is upregulated in various cancers such as glioblastoma [61, 62] . Thus, certain cancers may activate the demethylation programs normally seen in sperm to achieve a proliferative phenotype. It will be important to determine if ALKBH5 reshapes the epitranscriptome and whether this effect is necessary for cancer pathogenesis. In addition to cancer, ALKBH5 is highly induced in response to hypoxia [64] . It will, therefore be, important to determine if aspects of the cellular response to hypoxia involve mRNA demethylation. m 6 A levels are already known to be induced in response to specific stresses such as ultraviolet light and heat shock [9, 65, 66] . The induction of ALKBH5 by hypoxia raises the possibility that m 6 A may be reduced in response to other stresses. Although the field has evolved considerably, is now clear that FTO and ALKBH5 selectively demethylate m 6 A m and m 6 A, respectively, and their effects are likely to be highly selective on specific RNAs. Future research will need to focus on the identification of the specific transcripts that are the major targets of these enzymes and the mechanisms by which these enzymes are regulated to trigger RNA demethylation. 
